Skip to Main Content

Author Details

Vincent J Gnanapragasam
University of Cambridge
1999
163
37
PMIDPaper TitleJournal TitlePublished Year
36018819Clonal hematopoiesis and risk of prostate cancer in large samples of European ancestry men.Hum Mol Genet2023
37636205Composite risk stratification models optimise the value of imaging in prostate cancer staging.BJUI Compass2023
37614642Re-evaluating the diagnostic efficacy of PSA as a referral test to detect clinically significant prostate cancer in contemporary MRI-based image-guided biopsy pathways.J Clin Urol2023
37431085Implementation and yield of upfront genomic profiling in a clinical prostate cancer diagnostic pathway.BJU Int2023
36749370Time series radiomics for the prediction of prostate cancer progression in patients on active surveillance.Eur Radiol2023
36874604Prospective Implementation and Early Outcomes of a Risk-stratified Prostate Cancer Active Surveillance Follow-up Protocol.Eur Urol Open Sci2023
36912538Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.N Engl J Med2023
34255161Comparative performance of MRI-derived PRECISE scores and delta-radiomics models for the prediction of prostate cancer progression in patients on active surveillance.Eur Radiol2022
35495285A Feasibility Study of the Therapeutic Response and Durability of Short-term Androgen-targeted Therapy in Early Prostate Cancer Managed with Surveillance: The Therapeutics in Active Prostate Surveillance (TAPS01) Study.Eur Urol Open Sci2022
35696280How and when should radiologists report T-staging on MRI in patients with prostate cancer?BJU Int2022
35722245Rates of Positive Abdominal Computed Tomography and Bone Scan Findings Among Men with Cambridge Prognostic Group 4 or 5 prostate cancer: A Nationwide Registry Study.Eur Urol Open Sci2022
35659150Rare Germline Variants Are Associated with Rapid Biochemical Recurrence After Radical Prostate Cancer Treatment: A Pan Prostate Cancer Group Study.Eur Urol2022
36615017Development and External Validation of the STRATified CANcer Surveillance (STRATCANS) Multivariable Model for Predicting Progression in Men with Newly Diagnosed Prostate Cancer Starting Active Surveillance.J Clin Med2022
36661662Combining Molecular Subtypes with Multivariable Clinical Models Has the Potential to Improve Prediction of Treatment Outcomes in Prostate Cancer at Diagnosis.Curr Oncol2022
35933478Developing machine learning algorithms for dynamic estimation of progression during active surveillance for prostate cancer.NPJ Digit Med2022
35953766Assessing the impact of MRI based diagnostics on pre-treatment disease classification and prognostic model performance in men diagnosed with new prostate cancer from an unscreened population.BMC Cancer2022
35922801Urinary symptoms and prostate cancer-the misconception that may be preventing earlier presentation and better survival outcomes.BMC Med2022
36084119Evaluation of transabdominal and transperineal ultrasound-derived prostate specific antigen (PSA) density and clinical utility compared to MRI prostate volumes: A feasibility study.PLoS One2022
35075123Hyperpolarised <sup>13</sup>C-MRI identifies the emergence of a glycolytic cell population within intermediate-risk human prostate cancer.Nat Commun2022
35256616Author Correction: Hyperpolarised <sup>13</sup>C-MRI identifies the emergence of a glycolytic cell population within intermediate-risk human prostate cancer.Nat Commun2022
35024633Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium.Eur Urol Open Sci2022
34538077Serial changes in tumour measurements and apparent diffusion coefficients in prostate cancer patients on active surveillance with and without histopathological progression.Br J Radiol2022
32853339Germline Sequencing DNA Repair Genes in 5545 Men With Aggressive and Nonaggressive Prostate Cancer.J Natl Cancer Inst2021
33617330Risk-Based Selection for Active Surveillance: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Initiative.J Urol2021
33563540Comparison of initial and second opinion reads of multiparametric magnetic resonance imaging of the prostate for transperineal template-guided biopsies with MRI-Ultrasound fusion.Urol Oncol2021
33774889Does modern active surveillance offer an opportunity for new therapeutic strategies in early prostate cancer?BJU Int2021
33549512Application of a novel machine learning framework for predicting non-metastatic prostate cancer-specific mortality in men using the Surveillance, Epidemiology, and End Results (SEER) database.Lancet Digit Health2021
34936871Resolving the immune landscape of human prostate at a single-cell level in health and cancer.Cell Rep2021
34467563Robust and flexible inference for the covariate-specific receiver operating characteristic curve.Stat Med2021
34772971Clinical characteristics and outcomes for patients with nonâ¿¿metastatic castration-resistant prostate cancer.Sci Rep2021
34014596The diagnostic impact of UK regional variations in age-specific prostate-specific antigen guidelines.BJU Int2021
34155265MRI-derived radiomics model for baseline prediction of prostate cancer progression on active surveillance.Sci Rep2021
34241824Economic Evaluation of Transperineal versus Transrectal Devices for Local Anaesthetic Prostate Biopsies.Pharmacoecon Open2021
34162837Single cell derived mRNA signals across human kidney tumors.Nat Commun2021
33288843Discovery of PTN as a serum-based biomarker of pro-metastatic prostate cancer.Br J Cancer2021
33196886MRI-derived PRECISE scores for predicting pathologically-confirmed radiological progression in prostate cancer patients on active surveillance.Eur Radiol2021
33369808Rationalising the use of investigation for urinary tract infections: Analysis of 700 patients and proposal for a diagnostic algorithm.Int J Clin Pract2021
31564531Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance Initiative.Eur Urol Oncol2020
34337468Identification and Validation of Leucine-rich α-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification.Eur Urol Open Sci2020
31971823The effect of capped biparametric magnetic resonance imaging slots on weekly prostate cancer imaging workload.Br J Radiol2020
31737935Removing rician bias in diffusional kurtosis of the prostate using real-data reconstruction.Magn Reson Med2020
33072331Multicentre clinical evaluation of the safety and performance of a simple transperineal access system for prostate biopsies for suspected prostate cancer: The CAMbridge PROstate Biopsy DevicE (CamPROBE) study.J Clin Urol2020
33235229The effect of gadolinium-based contrast agent administration on magnetic resonance fingerprinting-based T<sub>1</sub> relaxometry in patients with prostate cancer.Sci Rep2020
33004514Extensive heterogeneity in somatic mutation and selection in the human bladder.Science2020
32773013Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.Health Technol Assess2020
32624282Erratum to 'Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received' [European Urology 77 (2020) 320-330].Eur Urol2020
32907896Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial.BMJ Open2020
32299423Clinical utility and cost modelling of the phi test to triage referrals into image-based diagnostic services for suspected prostate cancer: the PRIM (Phi to RefIne Mri) study.BMC Med2020
32166495Diagnostic accuracy of biparametric versus multiparametric prostate MRI: assessment of contrast benefit in clinical practice.Eur Radiol2020
32539712Comparative performance and external validation of the multivariable PREDICT Prostate tool for non-metastatic prostate cancer: a study in 69,206 men from Prostate Cancer data Base Sweden (PCBaSe).BMC Med2020
  • 1 - 50 of 163

Recommended Authors

Sebastiaan Remmers
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Career Start Year 2018
Number of shared co-authors 4
Adam B Weiner
Northwestern University Feinberg School of Medicine
Career Start Year 2013
Number of shared co-authors 3
Francesco Pellegrino
Urological Research Institute, IRCCS San Raffaele Hospital
Career Start Year 2012
Number of shared co-authors 2
Simpa S Salami
University of Michigan Medical School ann arbor
Career Start Year 2012
Number of shared co-authors 2
Giorgio Gandaglia
IRCCS San Raffaele Scientific Institute, Italy Vita-Salute San Raffaele University
Career Start Year 2012
Number of shared co-authors 6
Daniel E Spratt
University Hospitals Seidman Cancer Center, Case Western Reserve University
Career Start Year 2010
Number of shared co-authors 12
Jeffrey J Tosoian
Vanderbilt University Medical Center
Career Start Year 2008
Number of shared co-authors 6
Roderick C N van den Bergh
St. Antonius Hospital
Career Start Year 2007
Number of shared co-authors 7
Declan G Murphy
Peter MacCallum Cancer Centre, University of Melbourne
Career Start Year 2005
Number of shared co-authors 29
Derya Tilki
Universitatsklinikum Hamburg-Eppendorf
Career Start Year 2004
Number of shared co-authors 12
Ashley E Ross
Northwestern University
Career Start Year 2003
Number of shared co-authors 13
Alberto Briganti
IRCCS San Raffaele Scientific Institute
Career Start Year 2002
Number of shared co-authors 16
Robert Jeffrey Karnes
Mayo Clinic
Career Start Year 2000
Number of shared co-authors 12
Danny Vesprini
University of Toronto, Canada Odette Cancer Centre
Career Start Year 1998
Number of shared co-authors 11
Geert J L H van Leenders
Erasmus MC Cancer Institute, University Medical Center
Career Start Year 1998
Number of shared co-authors 15
Stephen J Freedland
Cedars-Sinai Medical Center
Career Start Year 1996
Number of shared co-authors 18
Inge M van Oort
Radboud University Medical Center
Career Start Year 1995
Number of shared co-authors 11
Markus Graefen
University Hospital Frankfurt, Goethe University Frankfurt am Main
Career Start Year 1993
Number of shared co-authors 15
Robert E Reiter
David Geffen School of Medicine at university of california los angeles
Career Start Year 1993
Number of shared co-authors 13
Alexandre R Zlotta
University Health Network, Princess Margaret Cancer Center, University of Toronto
Career Start Year 1993
Number of shared co-authors 8
Paul L Nguyen
Brigham and Women's Hospital and Dana Farber Cancer Institute, Harvard Medical School
Career Start Year 1990
Number of shared co-authors 11
Fred Saad
University of Montreal Health Center
Career Start Year 1990
Number of shared co-authors 14
Neil E Fleshner
University of Toronto
Career Start Year 1989
Number of shared co-authors 32
Christopher P Evans
University of California Davis
Career Start Year 1988
Number of shared co-authors 16
Philip Cornford
Liverpool University Hospitals
Career Start Year 1988
Number of shared co-authors 5
Alan W Partin
The Brady Urological Institute, Johns Hopkins University School of Medicine
Career Start Year 1987
Number of shared co-authors 17
Armen Aprikian
McGill University Health Centre, McGill University
Career Start Year 1987
Number of shared co-authors 14
Anders Bjartell
Skane University Hospital, Lund University
Career Start Year 1987
Number of shared co-authors 31
Eric A Klein
Cleveland Clinic
Career Start Year 1984
Number of shared co-authors 31
Bruce J Trock
Johns Hopkins University School of Medicine
Career Start Year 1984
Number of shared co-authors 9

Collaborators

Anne Y Warren
Cambridge University Hospitals National Health Service Foundation Trust
Co-authored papers 52
David E Neal
University of Oxford, John Radcliffe Hospital
Co-authored papers 28
Nimish Shah
Cambridge University Hospitals NHS Foundation Trust
Co-authored papers 16
Charlie E Massie
University of Cambridge
Co-authored papers 12
Andrew N Priest
University of Cambridge
Co-authored papers 10
Freddie C Hamdy
University of Oxford
Co-authored papers 9
Andy G Lynch
University of St Andrews
Co-authored papers 8
Colin S Cooper
Norwich Medical School, University of East Anglia
Co-authored papers 8
Zsofia Kote-Jarai
The Institute of Cancer Research
Co-authored papers 7
Hayley C Whitaker
University College London
Co-authored papers 6
Jeremy Clark
Norwich Medical School, University of East Anglia
Co-authored papers 6
Alastair D Lamb
University of Oxford
Co-authored papers 6
Jonathan Kay
University College London
Co-authored papers 6
David C Wedge
Manchester Cancer Research Centre, University of Manchester
Co-authored papers 6
Daniel S Brewer
University of Washington, USA Institute for Stem Cell and Regenerative Medicine
Co-authored papers 6
Edward Rowe
Bristol Urological Institute, Southmead Hospital
Co-authored papers 6
Monique J Roobol
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Co-authored papers 6
Rosalind A Eeles
The Institute of Cancer Research
Co-authored papers 6
Ian G Mills
Queen's University Belfast
Co-authored papers 5
Christopher S Foster
The Institute of Cancer Research
Co-authored papers 5
Adam Butler
Wellcome Sanger Institute
Co-authored papers 5
Peter Van Loo
The Francis Crick Institute
Co-authored papers 5
Mark Frydenberg
Monash University
Co-authored papers 5
Keiran Raine
Wellcome Sanger Institute
Co-authored papers 5
Ludmil B Alexandrov
Moores Cancer Center, university of california san diego
Co-authored papers 4
Sandra Edwards
The Institute of Cancer Research
Co-authored papers 4
Daniel M Berney
Barts Cancer Institute, Queen Mary University of London
Co-authored papers 4
Hayley J Luxton
University College London
Co-authored papers 4
Barbara Kremeyer
University College London
Co-authored papers 4
Alan Thompson
The Royal Marsden NHS Foundation Trust
Co-authored papers 4
Release 1.2